United States

Analyst Research Report Snapshot


RaQualia Pharma Inc. (4579) - Financial Analysis Review






06 Mar 2013





Companies referenced:


Available for Immediate Download

RaQualia Pharma Inc. (4579) - Financial Analysis Review Summary RaQualia Pharma Inc. (RaQualia) is a pharmaceutical company based in Japan. The company discovers, develops and markets clinical and pre-clinical candidates for human patients worldwide. The products of the company include anidulafungin, ziprasidone, dalbavancin, ep4 antagonist, cyclooxygenase-2 (cox-2) inhibitor, ghrelin receptor agonist, 5-ht4 partial agonist, acid pump antagonist, 5-ht2b antagonist, cb2 agonist, motilin receptor agonist and licensing. GlobalData's RaQualia Pharma Inc. (4579) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. RaQualia Pharma Inc. Key Recent Developments: Feb 22, 2013: RaQualia Pharma Receives Allowance For EP4 Antagonist Substance Patent In EU Nov 16, 2012: RaQualia Pharma Receives Allowance For Acid Pump Antagonist Substance Patent Nov 09, 2012: RaQualia Pharma Reports Nine Months Ended September 30, 2012 Results Oct 31, 2012: RaQualia Announces Joint Research Agreement With Ajinomoto Pharma To Discover New Gastrointestinal Treatments Aug 09, 2012: RaQualia Pharma Reports H1 2012 Results This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.